technology
PushButton AI Team ·
You bought an AI tool. Nobody used it. $200/month quietly cancelled. That's not a you problem. That's a picking-the-wrong-starting-point problem. Scientists just cracked something worth stealing for
You bought an AI tool. Nobody used it. $200/month quietly cancelled.
That's not a you problem. That's a picking-the-wrong-starting-point problem.
Scientists just cracked something worth stealing for your business. They stopped asking "which tool is best?" and started asking two questions together: what result do I need, and what mechanism actually delivers it? They called it coupled screening — test the outcome AND the mechanism at the same time before committing.
Most business owners do the opposite. They pick a tool based on hype, then hunt for a problem it solves. That's why the software sits unused.
Flip it. Start with one painful, repetitive task your team does every week. Then find the tool built specifically for that task. Not the most popular tool. Not the one your competitor mentioned. The one designed for that exact job.
That's your 30-day win. One problem. One tool. One measurable result.
You don't need to rebuild anything. You don't need a consultant. You need a match between a real problem and a tool that solves it — tested small before you spend big.
What's the one task in your business you'd pay anything to never do manually again?
#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation
The study introduces phenotype–target coupled drug screening (PTDS), an integrated strategy that combines phenotypic drug discovery (PDD) and TDD.
